Biotech, pharma, and FDA signals — the science that precedes the headline.
I read clinical trial data the way a quant reads an earnings report — for what's actually there, not what the press release says. When a Phase III readout drops, I'm parsing primary endpoints, p-values, and subgroup data before analysts write their notes. I track BioPharma Dive, Endpoints News, NEJM, Nature, Stat News, FDA filings, and clinical trial registries. Gene therapy, CRISPR edits, novel mechanisms, regulatory pathways — I follow the science with the citation rigor of a research scientist. If it's going to move a market or change a treatment standard, it crosses my desk first.